Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
22 09 2020
22 09 2020
Historique:
received:
02
07
2020
accepted:
17
07
2020
entrez:
11
9
2020
pubmed:
12
9
2020
medline:
15
5
2021
Statut:
ppublish
Résumé
The treatment of older, unfit patients with acute myeloid leukemia (AML) is challenging. Based on preclinical data of Bruton tyrosine kinase expression/phosphorylation and ibrutinib cytotoxicity in AML blasts, we conducted a randomized phase 2 multicenter study to assess the tolerability and efficacy of the addition of ibrutinib to 10-day decitabine in unfit (ie, Hematopoietic Cell Transplantation Comorbidity Index ≥3) AML patients and higher risk myelodysplasia patients (HOVON135/SAKK30/15 trial). In total, 144 eligible patients were randomly (1:1) assigned to either 10-day decitabine combined with ibrutinib (560 mg; sequentially given, starting the day after the last dose of decitabine) (n = 72) or to 10-day decitabine (n = 72). The addition of ibrutinib was well tolerated, and the number of adverse events was comparable for both arms. In the decitabine plus ibrutinib arm, 41% reached complete remission/complete remission with incomplete hematologic recovery (CR/CRi), the median overall survival (OS) was 11 months, and 2-year OS was 27%; these findings compared with 50% CR/CRi, median OS of 11.5 months, and 2-year OS of 21% for the decitabine group (not significant). Extensive molecular profiling at diagnosis revealed that patients with STAG2, IDH2, and ASXL1 mutations had significantly lower CR/CRi rates, whereas patients with mutations in TP53 had significantly higher CR/CRi rates. Furthermore, multicolor flow cytometry revealed that after 3 cycles of treatment, 28 (49%) of 57 patients with available bone marrow samples had no measurable residual disease. In this limited number of cases, measurable residual disease revealed no apparent impact on event-free survival and OS. In conclusion, the addition of ibrutinib does not improve the therapeutic efficacy of decitabine. This trial was registered at the Netherlands Trial Register (NL5751 [NTR6017]) and has EudraCT number 2015-002855-85.
Identifiants
pubmed: 32915972
pii: S2473-9529(20)31507-X
doi: 10.1182/bloodadvances.2020002846
pmc: PMC7509861
doi:
Substances chimiques
Piperidines
0
ibrutinib
1X70OSD4VX
Decitabine
776B62CQ27
Adenine
JAC85A2161
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4267-4277Informations de copyright
© 2020 by The American Society of Hematology.
Références
Cell Rep. 2017 Jul 18;20(3):572-585
pubmed: 28723562
Blood. 2009 Apr 30;113(18):4179-87
pubmed: 19008455
Blood Adv. 2018 Dec 26;2(24):3608-3617
pubmed: 30567725
J Clin Oncol. 2010 Feb 1;28(4):562-9
pubmed: 20026804
Br J Haematol. 2022 Aug;198(3):535-544
pubmed: 35438802
J Clin Oncol. 2013 Nov 1;31(31):3889-97
pubmed: 24062400
Blood. 2015 Jul 16;126(3):291-9
pubmed: 25987659
J Clin Oncol. 2012 Jul 20;30(21):2670-7
pubmed: 22689805
Leuk Lymphoma. 2014 Jul;55(7):1533-7
pubmed: 24144313
Leuk Lymphoma. 2013 Nov;54(11):2385-91
pubmed: 23425038
N Engl J Med. 2018 Mar 29;378(13):1189-1199
pubmed: 29601269
N Engl J Med. 2009 Sep 24;361(13):1235-48
pubmed: 19776405
Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7473-8
pubmed: 20368434
Leukemia. 2017 Apr;31(4):872-881
pubmed: 27740633
N Engl J Med. 2004 Apr 15;350(16):1617-28
pubmed: 15084694
Oncotarget. 2014 Oct 30;5(20):9930-8
pubmed: 25294819
N Engl J Med. 2016 Nov 24;375(21):2023-2036
pubmed: 27959731
Blood. 2015 Jan 29;125(5):767-74
pubmed: 25515963
Leukemia. 2018 Jan;32(1):241-244
pubmed: 28919634
J Clin Oncol. 2014 Apr 20;32(12):1242-8
pubmed: 24663049
Leuk Lymphoma. 2013 Sep;54(9):2003-7
pubmed: 23270581
Cancer. 2017 May 15;123(6):994-1002
pubmed: 28094841
J Clin Oncol. 2017 Aug 20;35(24):2745-2753
pubmed: 28486043
Leukemia. 2019 Jan;33(1):75-87
pubmed: 29977015
Blood. 2019 Jan 3;133(1):7-17
pubmed: 30361262
Br J Haematol. 2007 Feb;136(4):624-7
pubmed: 17223919
Am J Hematol. 2015 May;90(5):E77-9
pubmed: 25651001
J Clin Oncol. 2013 Nov 10;31(32):4123-31
pubmed: 24062403
Haematologica. 2016 Nov;101(11):e457-e460
pubmed: 27418649
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
Leukemia. 2014 Jan;28(1):78-87
pubmed: 24045501
Br J Haematol. 2017 Sep;178(5):810-812
pubmed: 27431572
Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):509-515.e1
pubmed: 31227358
Blood. 2014 Feb 20;123(8):1229-38
pubmed: 24307721
Sci Rep. 2015 Aug 21;5:12949
pubmed: 26292723
N Engl J Med. 2020 Aug 13;383(7):617-629
pubmed: 32786187
Clin Cancer Res. 2017 Nov 1;23(21):6430-6440
pubmed: 28765326
N Engl J Med. 2017 Aug 3;377(5):454-464
pubmed: 28644114
Cancer. 2015 Feb 15;121(4):556-61
pubmed: 25336333
Blood. 2018 Mar 22;131(12):1275-1291
pubmed: 29330221